Lejiao Jia
Overview
Explore the profile of Lejiao Jia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jia L, Yang H, Liu Y, Zhou Y, Li G, Zhou Q, et al.
J Nanobiotechnology
. 2024 Apr;
22(1):198.
PMID: 38649957
Heat shock protein 90 (HSP90) is overexpressed in numerous cancers, promotes the maturation of numerous oncoproteins and facilitates cancer cell growth. Certain HSP90 inhibitors have entered clinical trials. Although less...
2.
Jia L, Yang H, Zheng D, Ye J, Zhou Q, Li G, et al.
ACS Appl Mater Interfaces
. 2023 May;
15(23):27624-27637.
PMID: 37249260
Acute myeloid leukemia (AML) is rapidly progressed hematologic malignancy with relapsed and refractory characteristics. Cytarabine combined with the BCL2 inhibitor venetoclax showed impressive response rates in the treatment of relapsed/refractory...
3.
Li Z, Jia L, Tang H, Shen Y, Shen C
RSC Adv
. 2023 May;
13(20):13586-13591.
PMID: 37152572
A novel geldanamycin derivative LZY3016 was synthesized as an antitumor agent. Compound LZY3016 exhibited potent anti-proliferation activity toward MDA-MB-231 (IC = 0.06 μM), which was more effective than positive drug...
4.
Li Z, Jia L, Tang H, Shen Y, Shen C
RSC Adv
. 2022 May;
9(72):42509-42515.
PMID: 35542888
A novel geldanamycin-ferulic acid conjugate LZY228 was prepared and evaluated for anti-proliferation activity on human cancer cell line MDA-MB-231. Compound LZY228 exhibited potent cytotoxicity with IC value of 0.27 μM,...
5.
Zhou Y, Guan L, Li W, Jia R, Jia L, Zhang Y, et al.
Cancer Lett
. 2022 Mar;
533:215608.
PMID: 35240234
T-cell acute lymphoblastic leukemia (T-ALL) is a serious hematologic malignancy and glucocorticoid resistance is the main recurrent cause for a high relapsed and death rate. Here, we proposed an effective...
6.
Jia L, Li Z, Zheng D, Li Z, Zhao Z
Carbohydr Polym
. 2020 Nov;
251:117008.
PMID: 33142574
A novel folic acid mediated chitosan oligosaccharide-grafted disulfide-containing polyethylenimine copolymer-based silica nanohybrids were fabricated for co-delivering paclitaxel and P-shRNA. These nanoparticles could efficiently protect P-shRNA against degradation, and exhibited well...
7.
Li Z, Wu X, Jia L, Li J, Zhang R, Tang H, et al.
Bioorg Med Chem Lett
. 2020 Mar;
30(9):127070.
PMID: 32143887
A series of novel 2-arylbenzimidazoles have been designed, synthesized and evaluated for their inhibitory activity against IDH2 R140Q mutant. The preliminary results indicated that four compounds 7b, 7c, 7m and...
8.
Jia L, Li Z, Shen J, Zheng D, Tian X, Guo H, et al.
Int J Pharm
. 2015 May;
489(1-2):318-30.
PMID: 25956050
The objective of the study is to fabricate multifunctional mesoporous silica nanoparticles for achieving co-delivery of conventional antitumor drug paclitaxel (PTX) and the multidrug resistance reversal agent tetrandrine (TET) expecting...
9.
Li Z, Jia L, Xu H, Lu C, Shena Y
Med Chem
. 2014 Dec;
11(5):482-8.
PMID: 25537129
A series of 17-phenylpropylamine/phenoxyethylamine-substituted derivatives of geldanamycin (GA) was synthesized and evaluated for the anti-proliferation activity on human cancer cell line MDA-MB-231. All the derivatives exhibited potent cytotoxicity with IC50...
10.
Li Z, Jia L, Wang J, Wu X, Hao H, Wu Y, et al.
Eur J Med Chem
. 2014 Oct;
87:346-63.
PMID: 25277067
Heat shock protein 90 (Hsp90) is an attractive target for the development of antitumor agents. Geldanamycin (GA), the first Hsp90 inhibitor, has potent antitumor activity, but showed significant hepatotoxicity. To...